← Leaderboards
Mark C Genovese
Stanford University
$102,802
Attributed
$102,802
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $55.2K · FY2005–08$100K$75K$50K$25K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$102,802 · 9
By mechanism
M01$102,802 · 9
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Christopher H Contag$24,654,819
- Utkan Demirci$14,678,583
- Eric T. Kool$24,920,252
- Karl Alexander Deisseroth$77,564,196
- Jianghong Rao$21,022,312
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyComputer Retrieval Of Information On Scientific Projects DatabaseGrantUnited States National Institutes Of HealthSourceResourcesResearch PersonnelFundingInstitutionBaseRheumatoid ArthritisRheumatologyPharmaceutical PreparationsAmericanIndexingPlacebosDrug KineticsDoseEnd PointCollegeInflammatoryConditionEvaluationPurpose
Grant awards (9)
CLINICAL TRIAL: RITUXIMAB WITH OR WITHOUT METHOTREX IN PSORIATIC ARTHRITIS AND P$2,276
M01 · FY2008 · RR · contact PI
FONTOLIZUMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS$14,044
M01 · FY2007 · RR · contact PI
TUMOR NECROSIS FACTOR-ALPHA INHIBITION (ADALIMUMAB) IN OSTEOARTHRITIS$5,851
M01 · FY2007 · RR · contact PI
STUDY OF TACI-FC5 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)$1,755
M01 · FY2007 · RR · contact PI
STUDY OF TACI-FC5 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$25,352
M01 · FY2006 · RR · contact PI
TUMOR NECROSIS FACTOR-ALPHA INHIBITION (ADALIMUMAB) IN OSTEOARTHRITIS$19,571
M01 · FY2006 · RR · contact PI
MONOCLONAL ANTI-BLYS ANTIBODY IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$10,230
M01 · FY2006 · RR · contact PI
STUDY OF TACI-FC5 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$12,697
M01 · FY2005 · RR
MONOCLONAL ANTI-BLYS ANTIBODY IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$11,026
M01 · FY2005 · RR